SciELO - Scientific Electronic Library Online

 
vol.42 número1Reflexiones sobre la formación de un neurólogo clínico en Chile: la obligación de hacer lo mejor que podamosInterconsulta Neurológica en la Unidad de Tratamiento Intensivo índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

Compartir


Revista chilena de neuro-psiquiatría

versión On-line ISSN 0717-9227

Resumen

MIRANDA, Marcelo  y  AZALDEGUI, Octavio. Neuroprotective therapy in Parkinson’s Disease. Rev. chil. neuro-psiquiatr. [online]. 2004, vol.42, n.1, pp.49-52. ISSN 0717-9227.  http://dx.doi.org/10.4067/S0717-92272004000100007.

With the current limitations on treating Parkinson’s disease, neuroprotection should be looked at as a possible way of slowing the varying processes involved in the onset of the disease. A review was made of the work of NINDS experts, who evaluated 59 drugs resulting from their Medline and Pub Med search. Twelve drugs, those considered the most promising, were included in the final analysis. We look at such substances as caffeine, coenzyme q10, estrogens, minocycline, nicotine, rasagiline-selegiline, and ropinirole-pramipexole. These agents acted dissimilarly, but favorably, on some of the disease’s processes or on its underlying pathogenesis, although the mechanisms involved and the duration of the beneficial effects were not clear. The challenge is to overcome the difficulties that make the results of the few current studies uncertain, using new methods, such as transgenic models, to maintain hope for effective future treatments.

Palabras clave : Parkinson’s Disease; neuroprotective terapy.

        · texto en Español

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons